|
Bronchiectasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The MUC2 level (10.23±9.27 ng/mL) was significantly elevated in patients with ILD than in those with pleural effusion (6.21±3.28 ng/mL) or bronchiectasis (5.73±1.51 ng/mL) (both p<0.05).
|
30573494 |
2019 |
|
Lichen Sclerosus et Atrophicus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR results showed that LSA significantly increased the expression level of antioxidant genes (GSH-Px, SOD, Nrf2, HO-1), glycosyltransferase genes (GalNT1, GalNT3, GalNT7) and mucin gene (MUC2) in intestinal mucosa (<i>p</i> < 0.05).
|
31731602 |
2019 |
|
Tuberculosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The lipolytic protein LipU was conserved in mycobacterium sp. including M. tuberculosis (MTB LipU) and M. leprae (MLP LipU).
|
29557724 |
2019 |
|
Pancreatitis, Chronic
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
The combined detection in the feces and blood showed a 60% MUC2 methylation rate in PC (n = 10), which was higher than those in the CP (n = 5, 0%, P < 0.01) and CON (n = 12, 0%, P < 0.01).
|
31590960 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.010 |
Biomarker
|
disease |
BEFREE |
NEC was associated with ileal morphological injury and reduction in MUC2+ goblet cells and GRP94+ cells per villus.
|
30699187 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS: The high frequency of both MUC1 and MUC5AC cytoplasmic expression, coupled with a lack of MUC2 and MUC6 expression in ALK + lung cancer may contribute to the biologically aggressive behavior of ALK + cancer.
|
30580903 |
2019 |
|
Stage II Colon Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
|
31121192 |
2019 |
|
Gastrointestinal mucositis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.
|
30815720 |
2019 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS: The high frequency of both MUC1 and MUC5AC cytoplasmic expression, coupled with a lack of MUC2 and MUC6 expression in ALK + lung cancer may contribute to the biologically aggressive behavior of ALK + cancer.
|
30580903 |
2019 |
|
Mucinous breast cancer
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, our report identifies aberrant DNA methylation of MUC2 as a possible cause of extracellular production of mucin in MuBC.
|
30789657 |
2019 |
|
IIeocolitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Casp8<sup>∆IEC</sup> mice developed ileocolitis accompanied by changes in intestinal barrier morphology and reduced expression of barrier-related genes such as mucin-2 (<i>Muc2)</i> and defensins in the ileum and <i>Muc2</i> in the colon.
|
31411503 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS: The high frequency of both MUC1 and MUC5AC cytoplasmic expression, coupled with a lack of MUC2 and MUC6 expression in ALK + lung cancer may contribute to the biologically aggressive behavior of ALK + cancer.
|
30580903 |
2019 |
|
Mucinous carcinoma of breast
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Finally, our report identifies aberrant DNA methylation of MUC2 as a possible cause of extracellular production of mucin in MuBC.
|
30789657 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GNAS mutation is observed frequently in the intestinal subtype of IPMNs with MUC2 expression, and less frequently in IPMNs with concomitant pancreatic ductal adenocarcinoma (PDAC).
|
30879148 |
2019 |
|
Cavernous Hemangioma of Brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, loss of Mucin-2 or exposure to dietary emulsifiers that reduce the mucus barrier increases CCM burden analogous to loss of <i>Pdcd10</i> in the gut epithelium.
|
31776290 |
2019 |
|
Stage II Colon Cancer AJCC v7
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
|
31121192 |
2019 |
|
Stage II Colon Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
|
31121192 |
2019 |
|
Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NASH-TFF3 treated group had decreased expression levels of TLR4 and NF-κB and increased expression levels of Muc2 than NASH group.
|
31101239 |
2019 |
|
Dejerine-Sottas Disease (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Consistently, RB supplementation reduced pore forming tight junction protein claudin-2, increased barrier strengthening claudin-3, zonula occluden-1 protein content and mucin (MUC)-2 mRNA level, and activated AMP-activated protein kinase (AMPK) in DSS-treated mice.
|
29091813 |
2018 |
|
Jaundice, Obstructive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control group, the small intestinal mucosa was significantly damaged; goblet cells and MUC2 were significantly decreased and serum endotoxin level was significantly increased in patients and rats with obstructive jaundice.
|
29599128 |
2018 |
|
Muscle Cramp
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, pro-inflammatory cytokines TNF-α, IL-1β, IL-4 and IL-13, as well as chemokines CXCL2 and CXCL5 for neutrophils recruitment were significantly decreased in CRAMP-treated mice, and epithelial repair-related factors MUC2 and Claudin1 were increased, determined by real time-PCR and ELISAs.
|
29049008 |
2018 |
|
Precancerous Conditions
|
0.010 |
Biomarker
|
group |
BEFREE |
Results The optimal set of markers for detecting malignant potential was a panel of peptides from mucin-5AC and mucin-2, which could discriminate premalignant/malignant lesions from benign with an accuracy of 97% (95% CI, 89% to 99%) in the validation cohort.
|
29166170 |
2018 |
|
Salmonella infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Salmonella infection induces goblet cell loss and reduces MUC2 expression by increasing Dll1, Dll4, and HES1 expression, while L. acidophilus reverses epithelial damage by balancing the Notch pathway.
|
30198100 |
2018 |
|
Necrotic enteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Down-regulated expression levels of tight junction (TJ) proteins: junctional adhesion molecule 2 (JAM2), occluding, and intestinal mucin 2 (MUC2) by NE challenge, was up-regulated by the addition of AH (1 or 3%) supplementation.
|
29538713 |
2018 |
|
Infectious colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
High MUC2 production in inflammatory bowel disease and infectious colitis depletes goblet cells and the mucus layer by an unknown mechanism.
|
29545196 |
2018 |